Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Aug 25, 2021
Date Accepted: Feb 15, 2022

The final, peer-reviewed published version of this preprint can be found here:

An mHealth App to Support Caregivers in the Medical Management of Their Child With Cancer: Co-design and User Testing Study

Mueller EL, Cochrane AR, Campbell ME, Nikkhah S, Miller AD

An mHealth App to Support Caregivers in the Medical Management of Their Child With Cancer: Co-design and User Testing Study

JMIR Cancer 2022;8(1):e33152

DOI: 10.2196/33152

PMID: 35293867

PMCID: 8968552

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Co-Design and Testing of mHealth App to Support Caregivers in the Medical Management of their Child with Cancer

  • Emily L Mueller; 
  • Anneli R Cochrane; 
  • Madi E Campbell; 
  • Sarah Nikkhah; 
  • Andrew D Miller

ABSTRACT

Background:

Caregivers take on new challenges and tasks when their child is diagnosed with cancer, which can be overwhelming. Mobile technology has the capacity to provide in the moment support at their fingertips to aid in symptom tracking, medication management, and planning for emergencies.

Objective:

The objective of this study was to engage directly with end-users to co-design and create a mobile technology app to support caregivers in the medical management of their child with cancer.

Methods:

We engaged directly with caregivers of children with cancer and pediatric oncology nurse coordinators (proxy end-users) to co-design and create the prototype of the Cope 360 mHealth tool. Alpha testing was accomplished through walking the users through a series of pre-determined tasks that encompassed all aspects of the app including tracking symptoms, managing medications, and planning or practicing for a medical emergency that required seeking care in the emergency department. Evaluation was accomplished through recorded semi-structured interviews and quantitative surveys to capture demographics and measure the system usability score. Interviews were transcribed and analyzed iteratively using NVivo 12.

Results:

There were 8 caregivers (ages 33-50) of children with cancer with most children receiving chemotherapy and 6 nurse coordinators with half having 11-20 years of nursing experience. The mean system usability score was 89.4 (95% CI 80-98.8). The main themes found in the qualitative evaluation of caregivers’ experience with alpha testing included need for clarity in the medical information and terminology, improvement in design of tasks, tracking of symptoms including adjusting the look and feel of certain buttons, and changing the visual graph used to monitor symptoms to include date anchors.

Conclusions:

Further testing among caregivers in a real-world environment is needed to refine the final version of the Cope 360 tool prior to implementation within a randomized controlled trial.


 Citation

Please cite as:

Mueller EL, Cochrane AR, Campbell ME, Nikkhah S, Miller AD

An mHealth App to Support Caregivers in the Medical Management of Their Child With Cancer: Co-design and User Testing Study

JMIR Cancer 2022;8(1):e33152

DOI: 10.2196/33152

PMID: 35293867

PMCID: 8968552

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.